Compare CRAI & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRAI | AMPH |
|---|---|---|
| Founded | 1965 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 1998 | 2005 |
| Metric | CRAI | AMPH |
|---|---|---|
| Price | $177.21 | $26.42 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 2 | 7 |
| Target Price | ★ $250.50 | $22.50 |
| AVG Volume (30 Days) | 87.5K | ★ 479.1K |
| Earning Date | 10-29-2026 | 11-05-2026 |
| Dividend Yield | ★ 1.29% | N/A |
| EPS Growth | ★ 20.77 | N/A |
| EPS | ★ 8.14 | 0.81 |
| Revenue | ★ $751,583,000.00 | $719,887,000.00 |
| Revenue This Year | $8.35 | $3.87 |
| Revenue Next Year | $4.01 | $4.90 |
| P/E Ratio | ★ $21.75 | $32.62 |
| Revenue Growth | ★ 9.33 | N/A |
| 52 Week Low | $132.17 | $16.65 |
| 52 Week High | $227.29 | $29.52 |
| Indicator | CRAI | AMPH |
|---|---|---|
| Relative Strength Index (RSI) | 61.97 | 57.65 |
| Support Level | $153.02 | $25.23 |
| Resistance Level | $194.00 | $29.40 |
| Average True Range (ATR) | 4.99 | 0.82 |
| MACD | 0.99 | -0.11 |
| Stochastic Oscillator | 85.50 | 39.08 |
CRA International Inc is a consulting firm specializing in providing economic, financial and management consulting services. The company provides advisory services on economic and financial matters related to litigation and regulatory proceedings, and advises corporations on business and performance-related matters. Its consulting services are organized into two areas: litigation, regulatory and financial consulting, and management consulting. The company's clients include domestic and foreign companies, government agencies, public and private utilities, and national and international trade associations. It derives revenues by providing professional and consulting services. Geographically, the maximum revenue is derived from the United States, followed by United Kingdom and other regions.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.